NCT07318155RecruitingPhase 2
A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease
A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of Subcutaneously Administered SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease
Source: ClinicalTrials.gov · Last updated 29 Apr 2026
Brief summary (registry, in English)
The study is a Phase 2a, randomized, double-blind, placebo-controlled, sequential cohort study to evaluate the pharmacodynamics (PD), safety and pharmacokinetics (PK) of multiple doses of SRSD107 in participants with coronary arterial disease (CAD) and/or peripheral arterial disease (PAD) with aspirin as background concomitant therapy.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 104 (estimated)
- First submitted
- 7 Dec 2025
- Start date
- 11 Mar 2025
- Primary completion date
- Dec 2027
- Lead sponsor
- Sirius Therapeutics Co., Ltd.
- Diseases
- Coronary artery disease
- NCT number
- NCT07318155
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 104
- From 11 Mar 2025 to the primary completion date, Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Receipt of an investigational drug (IP) within 30 days or 5 half-lives of that drug, whichever is longer, prior to dose administration in this study.
- Previous use of SRSD107.
Other illness
- Known bleeding disorder
- Genetic cardiomyopathies or other non-ischemic cardiomyopathies that are not related to atherosclerotic cardiovascular disease.
- History of ethanol abuse or addictive drug use (cannabis products allowed) within 6 months of screening.
Lab values
- Severe heart failure with known left ventricular ejection fraction \<35%, or New York Heart Association (NYHA) class III or IV symptoms.
Who the study is looking for
- Able to comprehend and willing to sign an ICF and to abide by the study restrictions.
- Males or females aged 18 to 75 years, inclusive.
- Body mass index (BMI) between 18.0 and 35.0 kg/m2, inclusive.
- History of chronic coronary and/or peripheral arterial disease
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fuwai Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.